OncoMatch/Clinical Trials/NCT04550104
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Is NCT04550104 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for non small cell lung cancer.
Treatment: Olaparib Oral Tablet [Lynparza] · AZD1390 · Ceralasertib · AZD5305 · Durvalumab — CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC, followed by up to 12 months of consolidation durvalumab immunotherapy in selected study arms. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within each of the experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to 13.5 months post start of radiotherapy and use these to inform dose escalation decision making.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IIB, III
Prior therapy
Cannot have received: thoracic radiotherapy
Prior thoracic radiotherapy
Cannot have received: pneumotoxic drugs (busulfan, bleomycin)
Exception: If prior therapy in lifetime, then exclude if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.
Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then exclude if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.
Cannot have received: anti-PD-1 or anti-PD-L1 treatment
Patients who have received prior anti-PD-1 or anti PD-L1 treatment
Cannot have received: autologous or allogeneic organ or tissue transplantation
Received a prior autologous or allogeneic organ or tissue transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify